A multifaceted cancer immunotherapy based on an immune checkpoint-modulating chimeric oncolytic virus vector in combination with a dendritic cell vaccine

Project Information

ONCO-VAX

Grant agreement ID: 853433

DOI

10.3030/853433

Project closed

EC signature date 18 March 2020

Start date 1 April 2020

End date 31 March 2026

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 1 499 988,00

EU contribution

€ 1 499 988,00

Coordinated by

KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies

Author(s): Dirk M. Nettelbeck, Mathias F. Leber, Jennifer Altomonte, Assia Angelova, Julia Beil, Susanne Berchtold, Maike Delic, Jürgen Eberle, Anja Ehrhardt, Christine E. Engeland, Henry Fechner, Karsten Geletneky, Katrin Goepfert, Per Sonne Holm, Stefan Kochanek, Florian Kreppel, Lea Krutzke, Florian Kühnel, Karl Sebastian Lang, Antonio Marchini, Markus Moehler, Michael D. Mühlebach, Ulrike Naumann, Rom
Published in: Viruses, Issue 13/8, 2021, Page(s) 1420, ISSN 1999-4915
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/v13081420

Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma

Author(s): Teresa Krabbe, Janina Marek, Tanja Groll, Katja Steiger, Roland M. Schmid, Angela M. Krackhardt, Jennifer Altomonte
Published in: Cancers, Issue 13/5, 2021, Page(s) 1044, ISSN 2072-6694
Publisher: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/cancers13051044

Intellectual Property Rights

Patent (2)

AN IMMUNE CHECKPOINT-MODULATING VSV-NDV HYBRID VIRUS FOR ONCOLYTIC VIRUS IMMONOTHERAPY OF CANCER

Application/Publication number: 20 205209
Date: 2020-11-02
Applicant(s): KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)

AN IMMUNE CHECKPOINT-MODULATING VSV-NDV HYBRID VIRUS FOR ONCOLYTIC VIRUS IMMONOTHERAPY OF CANCER

Application/Publication number: 20 205209
Date: 2020-11-02
Applicant(s): KLINIKUM DER TECHNISCHEN UNIVERSITÄT MÜNCHEN (TUM KLINIKUM)